Table 3.
Study (n) | Regimen | ORR (CR + PR), % | Median PFS, months | Median OS, months |
---|---|---|---|---|
Matulonis et al. [42] |
Cediranib 45 mg/day |
17 |
5.2 |
Not reached |
(n = 46) | ||||
Ledermann et al. [43] |
Cediranib 20 mg/day → cedarinib maintenance vs. placebo |
– |
Restricted mean survival time, months |
Restricted mean survival time, months |
(n = 456) |
11.4 vs. 9.4 |
20.3 vs. 17.6 |
||
Du Bois et al. [44] |
Pazopanib 800 mg/day vs. placebo |
– |
17.9 vs. 12.3 |
Not reached |
(n = 940) | ||||
Campos et al. [45] |
Sunitinib 37.5 mg/day |
8.3 |
9.9b |
– |
(n = 35) | ||||
Biagi et al. [46] |
Sunitinib 50 mg/day (int.) |
13.3 |
4.1 |
– |
(n = 30) | ||||
Baumann et al. [47] |
Sunitinib 50 mg/day (int.) vs. 37.5 mg/day (cont.) |
16.7 vs. 5.4 |
4.8 vs. 2.9 |
13.6 vs. 13.7 |
(n = 73) | ||||
Matei et al. [48] |
Sorafenib 400 mg b.i.d. |
3.4 |
6-month PFS rate: 24% |
– |
(n = 71) | ||||
Herzog et al. [49] |
Sorafenib 400 mg b.i.d. vs. placebo |
– |
386 vs. 478a |
– |
(n = 249) | ||||
Ledermann et al. [50] |
Nintedanib 250 mg b.i.d. vs. placebo |
– |
36-week PFS rate: |
– |
(n = 83) |
16.3% vs. 5.0% |
|||
Du Bois et al. [51] |
Nintedanib 200 mg b.i.d. + CP vs. nintedanib + placebo |
– |
17.3 vs. 16.6 |
– |
(n = 1,366) | ||||
Coleman et al. [52] |
Aflibercept 6 mg/kg + D |
54 |
6.2 |
24.3 |
(n = 46) | ||||
Gotlieb et al. [53] |
Aflibercept 4 mg/kg vs. placebo |
– |
6.3 vs. 7.3b |
12.9 vs. 16.0b |
(n = 55) | ||||
Colombo et al. [54] |
Aflibercept 4 mg/kg |
– |
8.5b |
– |
(n = 16) | ||||
Karlan et al. [55] |
Trebananib 10 mg/kg + P vs. trebananib 3 mg/kg + P vs. placebo + P |
37 vs. 19 vs. 27 |
7.2 vs. 5.7 vs. 4.6 |
22.5 vs. 20.4 vs. 20.9 |
(n = 161) | ||||
Monk et al. [56] |
Trebananib 15 mg/kg + P vs. placebo + P |
38 vs. 30 |
7.2 vs. 5.4 |
19.0c vs. 17.3c |
(n = 919) |
b.i.d. = twice daily. cont = continuous. CR = complete response. D = docetaxel. int = intermittent. ORR = objective response rate. OS = overall survival. PFS = progression-free survival. P = paclitaxel. PR = partial response.
aTime in days.
bTime in weeks.
CInterim data.